Jazz Pharmaceuticals
JAZZJazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2022-2024
All insider trades at Jazz Pharmaceuticals
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 3/7/2024 | Sell | Carr, Patricia | SVP, Chief Accounting Officer | $117.0 | $206,821 |
| 3/6/2024 | Sell | Carr, Patricia | SVP, Chief Accounting Officer | $119.2 | $231,628 |
| 3/1/2024 | Buy | Johnson, Philip L. | EVP & Chief Financial Officer | $119.7 | $1,435,800 |
| 12/4/2023 | Sell | Cook, Jennifer E. | Director | $119.3 | $49,736 |
| 12/4/2023 | Sell | Smith, Mark Douglas | Director | $119.3 | $49,736 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)